EE200000743A - Crystalline Efavirenz - Google Patents

Crystalline Efavirenz

Info

Publication number
EE200000743A
EE200000743A EEP200000743A EEP200000743A EE200000743A EE 200000743 A EE200000743 A EE 200000743A EE P200000743 A EEP200000743 A EE P200000743A EE P200000743 A EEP200000743 A EE P200000743A EE 200000743 A EE200000743 A EE 200000743A
Authority
EE
Estonia
Prior art keywords
crystalline efavirenz
efavirenz
crystalline
Prior art date
Application number
EEP200000743A
Other languages
Estonian (et)
Inventor
A. Radesca Lilian
B. Maurin Michael
R. Rabel Shelley
R. Moore James
Original Assignee
Dupont Pharmaceuticals Company
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=22214647&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=EE200000743(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Dupont Pharmaceuticals Company filed Critical Dupont Pharmaceuticals Company
Publication of EE200000743A publication Critical patent/EE200000743A/en
Publication of EE05547B1 publication Critical patent/EE05547B1/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D265/00—Heterocyclic compounds containing six-membered rings having one nitrogen atom and one oxygen atom as the only ring hetero atoms
    • C07D265/04—1,3-Oxazines; Hydrogenated 1,3-oxazines
    • C07D265/12—1,3-Oxazines; Hydrogenated 1,3-oxazines condensed with carbocyclic rings or ring systems
    • C07D265/14—1,3-Oxazines; Hydrogenated 1,3-oxazines condensed with carbocyclic rings or ring systems condensed with one six-membered ring
    • C07D265/18—1,3-Oxazines; Hydrogenated 1,3-oxazines condensed with carbocyclic rings or ring systems condensed with one six-membered ring with hetero atoms directly attached in position 2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
EEP200000743A 1998-06-11 1999-06-10 Crystalline Efavirenz EE05547B1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US8898198P 1998-06-11 1998-06-11
PCT/US1999/013199 WO1999064405A1 (en) 1998-06-11 1999-06-10 Crystalline efavirenz

Publications (2)

Publication Number Publication Date
EE200000743A true EE200000743A (en) 2002-10-15
EE05547B1 EE05547B1 (en) 2012-06-15

Family

ID=22214647

Family Applications (1)

Application Number Title Priority Date Filing Date
EEP200000743A EE05547B1 (en) 1998-06-11 1999-06-10 Crystalline Efavirenz

Country Status (21)

Country Link
EP (1) EP1086087A1 (en)
JP (1) JP2002517487A (en)
CN (1) CN1307568A (en)
AR (3) AR018670A1 (en)
AU (1) AU758114C (en)
BR (1) BR9911523A (en)
CA (1) CA2333550A1 (en)
EE (1) EE05547B1 (en)
HR (1) HRP990182A2 (en)
HU (1) HUP0103819A3 (en)
IL (1) IL139793A (en)
MY (1) MY126450A (en)
NO (1) NO20006255L (en)
NZ (1) NZ507713A (en)
PL (1) PL198504B1 (en)
SG (3) SG111980A1 (en)
SK (1) SK18182000A3 (en)
TW (1) TWI235152B (en)
UA (1) UA74324C2 (en)
WO (1) WO1999064405A1 (en)
ZA (1) ZA200006173B (en)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5965729A (en) 1997-02-05 1999-10-12 Merck & Co., Inc. Process for the crystallization of a reverse transcriptase inhibitor using an anti-solvent
US20060235008A1 (en) 2004-08-19 2006-10-19 Hetero Drugs Limited Novel polymorphs of efavirenz
US7205402B2 (en) * 2004-09-02 2007-04-17 Bristol-Myers Squibb Company Synthesis of a benzoxazinone
WO2008108630A1 (en) * 2007-03-02 2008-09-12 Ultimorphix Technologies B.V. Polymorphic forms of efavirenz
WO2009011567A1 (en) * 2007-07-16 2009-01-22 Ultimorphix Technologies B.V. Crystalline forms of efavirenz
KR20130087048A (en) 2008-02-04 2013-08-05 화이자 리미티드 Polymorphic form of a [1,2,4]triazolo[4,3-a]pyridine derivative for treating inflammatory diseases
EP2367804B1 (en) 2008-12-22 2013-11-06 Hetero Research Foundation Process for preparing efavirenz polymorph
DE102009041443A1 (en) 2009-09-16 2011-03-31 Archimica Gmbh Salts of 6-chloro-4- (cyclopropylethynyl) -1,4-dihydro-4- (trifluoromethyl) -2H-3,1-benzoxazin-2-one and their synthesis, purification and use as precursors of efavirenz
EP2471783A1 (en) 2010-12-23 2012-07-04 Esteve Química, S.A. Novel polymorphic form of efavirenz
CN103508973B (en) * 2012-06-25 2016-04-27 上海迪赛诺药业有限公司 Prepare the method for efavirenz I type crystallization
CN102924398B (en) * 2012-11-22 2015-11-18 安徽贝克生物制药有限公司 For removing the method for the corresponding isomer of efavirenz
AU2013375157B2 (en) * 2013-01-23 2018-07-12 Alienor Farma Increased dosage of Efavirenz for the treatment of cancer
CN105037175B (en) * 2014-07-18 2017-02-22 盐城迪赛诺制药有限公司 Method of improving optical purity of efavirenz intermediate
CN105001101B (en) * 2015-05-28 2017-11-28 乐平市瑞盛制药有限公司 A kind of synthetic method of the trifluoroacetyl aniline hydrate hydrochloride of 4 chlorine 2
CN108947855B (en) * 2018-08-10 2021-10-22 江苏沙星化工有限公司 Synthesis method of efavirenz key intermediate

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL106507A (en) * 1992-08-07 1997-11-20 Merck & Co Inc Pharmaceutical compositions containing benzoxazinones and some novel compounds of this type
AU1694295A (en) * 1994-01-28 1995-08-15 Merck & Co., Inc. Benzoxazinones as inhibitors of hiv reverse transcriptase
US5633405A (en) * 1995-05-25 1997-05-27 Merck & Co., Inc. Asymmetric synthesis of (-)-6-chloro-4-cyclopropyl-ethynyl-4-trifluoromethyl-1,4-dihydro-2H-3,1-benzoxanzin-2-one
WO1998004535A1 (en) * 1996-07-26 1998-02-05 Du Pont Pharmaceuticals Company A practical synthesis of benzoxazinones useful as hiv reverse transcriptase inhibitors
AU4802797A (en) * 1996-10-02 1998-04-24 Du Pont Pharmaceuticals Company 4,4-disubstituted-1,4-dihydro-2h-3,1-benzoxazin-2-ones useful as hiv rever se transcriptase inhibitors and intermediates and processes for making the same
CN1073991C (en) * 1997-02-05 2001-10-31 麦克公司 Process for crystallization of reverse transcriptase inhibitor using anti-solvent

Also Published As

Publication number Publication date
EP1086087A1 (en) 2001-03-28
HRP990182A2 (en) 2000-02-29
UA74324C2 (en) 2005-12-15
SG111981A1 (en) 2005-06-29
ZA200006173B (en) 2001-10-31
WO1999064405A1 (en) 1999-12-16
SK18182000A3 (en) 2001-08-06
AR077407A2 (en) 2011-08-24
AU758114B2 (en) 2003-03-13
PL345221A1 (en) 2001-12-03
IL139793A0 (en) 2002-02-10
AU4436499A (en) 1999-12-30
HUP0103819A2 (en) 2002-02-28
NO20006255D0 (en) 2000-12-08
HUP0103819A3 (en) 2003-05-28
PL198504B1 (en) 2008-06-30
AR018670A1 (en) 2001-11-28
BR9911523A (en) 2001-09-18
CA2333550A1 (en) 1999-12-16
NO20006255L (en) 2001-02-12
NZ507713A (en) 2003-08-29
TWI235152B (en) 2005-07-01
IL139793A (en) 2006-10-31
JP2002517487A (en) 2002-06-18
SG134977A1 (en) 2007-09-28
AR077469A2 (en) 2011-08-31
SG111980A1 (en) 2005-06-29
AU758114C (en) 2003-10-30
CN1307568A (en) 2001-08-08
EE05547B1 (en) 2012-06-15
MY126450A (en) 2006-10-31

Similar Documents

Publication Publication Date Title
ATE341990T1 (en) SIGMIDOSCOPE
PT1119430E (en) STRAWBERRY
ID23761A (en) SUBSTITUTED TRISICLIC
EE200100135A (en) Crystalline forms of EtO2C-CH2- (R) Cgl-Aze-Pab-OH
DE59906732D1 (en) adjustment
ID24221A (en) PATRUM PLACE
EE200000743A (en) Crystalline Efavirenz
ATE262513T1 (en) BENZOYLPYRIDAZINE
ID23219A (en) SUBSTITUTED TRISICLIC
DE69714228D1 (en) CRYSTALLINE METALLOPHOSPHATE
FI980222A0 (en) Stycke av isoleringsaemne med en genomgaoende primaerstroemledning
PT1102747E (en) OSANETANT CRYSTALLINE FORMS
DE1118098T1 (en) MEHRFACHFLUSSIGELEKTROSPRÜHSCHNITTSTELLE
DE19842103B4 (en) Stanznietzuführung
FI980856A0 (en) Andningsskydd utrustad med en identifierare
DE59912532D1 (en) SUBSTITUTED ACYLAMINOPHENYL-URACILE
DE59912188D1 (en) SUBSTITUTED PHENYLURACILE
DE59911610D1 (en) SUBSTITUTED BENZOYLCYCLOHEXANDIONE
PT1076660E (en) (4-BROMOPYRAZOL-3-YL) -BZZAZOLES
FI980053A0 (en) Anordning Foer utformande av fiberbollar av laongstraeckta fibrer som foeljer med enluftstroem
ATA126298A (en) VERPUFFUNGSKLAPPE
DE29809642U1 (en) Mürbehammer
DE29802605U1 (en) Etagère
FI980596A0 (en) Koerljussystem med blaendskyddsanordning
FI980817A0 (en) Anordning Foer placering i samband med en telefonapparat